Enlivex Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENLV Nasdaq 2836 www.enlivex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enlivex Ltd.

Enlivex advances Allocetra while expanding into prediction markets - May 11th, 2026 11:39 am
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress - Apr 23rd, 2026 6:30 am
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook - Apr 20th, 2026 8:46 pm
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares - Apr 8th, 2026 6:30 am
Enlivex Therapeutics Q4 Earnings Call Highlights - Mar 25th, 2026 8:18 am
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Mar 20th, 2026 7:00 am
Enlivex Therapeutics announces new listing of RAIN token on Kraken - Feb 11th, 2026 6:11 am
RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance - Feb 9th, 2026 12:30 pm
RedChip Spotlights the Future of Finance at Fintech & Digital Asset Treasury Strategy (DATS) Virtual Investor Conference on February 4 - Jan 27th, 2026 7:35 am
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq - Jan 23rd, 2026 6:00 am
Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market - Nov 25th, 2025 10:14 am
Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120% - Nov 24th, 2025 2:51 pm
BC-Most Active Stocks - Nov 24th, 2025 8:30 am
Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy - Nov 24th, 2025 6:00 am
EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play - Nov 24th, 2025 5:46 am
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis - Nov 24th, 2025 4:40 am
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - Oct 28th, 2025 6:15 am
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Oct 3rd, 2025 7:00 am
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program - Sep 29th, 2025 6:15 am